Key Highlights
- Electra Therapeutics appoints Graham Parry, PhD, as Chief Scientific Officer.
- Kim-Hien Dao, DO, PhD, named Chief Medical Officer at Electra Therapeutics.
- New executives bring extensive drug development experience to the company.
- ELA026, a lead candidate for sHLH, showing promising clinical proof-of-concept.
Source: Business Wire
Notable Quotes
- “We are delighted to have such exceptional leaders as Graham and Kim-Hien join our management team at a time of great momentum for the company, with clinical proof-of-concept established for our lead candidate, ELA026,” — Kathy Dong, PharmD, MBA, President and Chief Executive Officer at Electra Therapeutics
- “I am enthusiastic about Electra’s approach to combining rigorous research and novel biology to deliver new therapies to under-served patient populations. The opportunity to work alongside this outstanding team with such a clear and focused mission is truly a privilege,” — Dr. Graham Parry, Chief Scientific Officer at Electra Therapeutics
- “I am delighted to take on this role during such an exciting time at Electra as the company advances ELA026 as a promising new therapy for patients with sHLH who currently lack effective treatment options,” — Dr. Kim-Hien Dao, Chief Medical Officer at Electra Therapeutics
SoHC's Take
The strategic appointments of Dr. Graham Parry as Chief Scientific Officer and Dr. Kim-Hien Dao as Chief Medical Officer at Electra Therapeutics are significant steps in reinforcing the company’s leadership at a pivotal moment. Their extensive backgrounds in drug development, particularly in advancing novel therapies through clinical trials, position Electra Therapeutics for continued success. With ELA026 showing strong clinical proof-of-concept, these appointments are likely to accelerate its path toward regulatory approval and expand its potential applications. This reinforces Electra’s commitment to addressing critical unmet needs in immunological diseases and cancer, promising innovative solutions for patients lacking effective treatment options.
